DiaMedica Therapeutics (DMAC) Total Non-Current Liabilities (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Total Non-Current Liabilities of $97000.0 for Q1 2026, down 54.03% year-over-year from $211000.0 in Q1 2025, and down 24.22% quarter-over-quarter from $128000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $97000.0 for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 54.03% year-over-year to $97000.0; the TTM figure through Mar 2026 stood at $97000.0 (down 54.03% YoY), while the FY2025 annual figure was $128000.0, down 45.99% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $97000.0, down from $128000.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $420000.0 in Q3 2022, with the low at $7000.0 in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $263000.0 (2024), against an average of $240823.5.
- Peak annual rise in Total Non-Current Liabilities reached 13233.33% in 2022, while the deepest fall reached 72.73% in 2022.
- DiaMedica Therapeutics' Total Non-Current Liabilities stood at $400000.0 in 2022, then slipped by 20.75% to $317000.0 in 2023, then declined by 25.24% to $237000.0 in 2024, then plunged by 45.99% to $128000.0 in 2025, then retreated by 24.22% to $97000.0 in 2026.
- Business Quant data shows DMAC's Total Non-Current Liabilities at $97000.0 in Q1 2026, $128000.0 in Q4 2025, and $157000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | 69,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69,000.00 |
| Mar 31, 2026 | 97,000.00 |
| Dec 31, 2025 | 128,000.00 |
| Sep 30, 2025 | 157,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Mar 31, 2025 | 211,000.00 |
| Dec 31, 2024 | 237,000.00 |
| Sep 30, 2024 | 263,000.00 |
| Jun 30, 2024 | 288,000.00 |
| Mar 31, 2024 | 294,000.00 |
| Dec 31, 2023 | 317,000.00 |
| Sep 30, 2023 | 340,000.00 |
| Jun 30, 2023 | 361,000.00 |
| Mar 31, 2023 | 381,000.00 |
| Dec 31, 2022 | 400,000.00 |
| Sep 30, 2022 | 420,000.00 |
| Jun 30, 2022 | 7,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Sep 30, 2021 | 4,000.00 |